IUPHAR Themed Review: The Gut Microbiome in Schizophrenia DOI Creative Commons
Srinivas Kamath,

Elysia Sokolenko,

Kate Collins

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107561 - 107561

Published: Dec. 1, 2024

Gut microbial dysbiosis or altered gut consortium, in schizophrenia suggests a pathogenic role through the gut-brain axis, influencing neuroinflammatory and neurotransmitter pathways critical to psychotic, affective, cognitive symptoms. Paradoxically, conventional psychotropic interventions may exacerbate this dysbiosis, with antipsychotics, particularly olanzapine, demonstrating profound effects on architecture disruption of bacterial phyla ratios, diminished taxonomic diversity, attenuated short-chain fatty acid synthesis. To address these challenges, novel therapeutic strategies targeting microbiome, encompassing probiotic supplementation, prebiotic compounds, faecal microbiota transplantation, rationalised co-pharmacotherapy, show promise attenuating antipsychotic-induced metabolic disruptions while enhancing efficacy. Harnessing such insights, precision medicine approaches transform antipsychotic prescribing practices by identifying patients at risk side based their profiles. This IUPHAR review collates current literature landscape axis its intricate relationship advocating for integrating microbiome assessments management. Such fundamental shift proposing microbiome-informed prescriptions optimise efficacy reduce adverse impacts would align treatments safety, prioritising 'gut-neutral' gut-favourable drugs safeguard long-term patient outcomes therapy.

Language: Английский

IUPHAR Themed Review: The Gut Microbiome in Schizophrenia DOI Creative Commons
Srinivas Kamath,

Elysia Sokolenko,

Kate Collins

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107561 - 107561

Published: Dec. 1, 2024

Gut microbial dysbiosis or altered gut consortium, in schizophrenia suggests a pathogenic role through the gut-brain axis, influencing neuroinflammatory and neurotransmitter pathways critical to psychotic, affective, cognitive symptoms. Paradoxically, conventional psychotropic interventions may exacerbate this dysbiosis, with antipsychotics, particularly olanzapine, demonstrating profound effects on architecture disruption of bacterial phyla ratios, diminished taxonomic diversity, attenuated short-chain fatty acid synthesis. To address these challenges, novel therapeutic strategies targeting microbiome, encompassing probiotic supplementation, prebiotic compounds, faecal microbiota transplantation, rationalised co-pharmacotherapy, show promise attenuating antipsychotic-induced metabolic disruptions while enhancing efficacy. Harnessing such insights, precision medicine approaches transform antipsychotic prescribing practices by identifying patients at risk side based their profiles. This IUPHAR review collates current literature landscape axis its intricate relationship advocating for integrating microbiome assessments management. Such fundamental shift proposing microbiome-informed prescriptions optimise efficacy reduce adverse impacts would align treatments safety, prioritising 'gut-neutral' gut-favourable drugs safeguard long-term patient outcomes therapy.

Language: Английский

Citations

1